16 February 2023, BUSSUM, The Netherlands — In a recent B financing round, Nextkidney is happy to report that the company has raised 11.9 million euros. The B round included 4.1 million euros in crowdfunding (headed by OnePlanetCrowd) and 7.8 million euros from official and informal investors in France and the Netherlands. The money will be utilized for the company’s revolutionary portable device’s market approval and clinical studies.
In public health policy, the management of renal failure is becoming more and more critical. With over $40 Bio spent in 2020 in only the United States alone, it is one of the significant contributors to healthcare expenses in western cultures, where the number of renal patients requiring dialysis is increasing by 6% per year.
Chief Executive Officer of Nextkidney BV, Jérôme Augustin: “The desire for a device that tackles existing workforce, logistical, and patient quality of life challenges are driven by the continuous expansion of the worldwide dialysis business. The NeokidneyTM does this by enabling patients to complete dialysis treatments anywhere, at any time, without being constrained by infrastructure or fluid logistics, allowing patients to maintain longer-lasting social and professional connections.”
The NeokidneyTM will enhance patient outcomes and financial viability. With a user-friendly interface and a small physical footprint in patients’ homes, its award-winning design improves the dialysis experience for patients. Its sorbent technology significantly decreases the amount of fluid and energy used, resulting in dialysis therapy results that are comparable to those of cutting-edge home hemodialysis machines. Dialysis is now much more flexible for patients thanks to the NeokidneyTM!
According to Nextkidney’s CFO, John Stooker, “We are happy to have received this considerable amount of capital, which will enable us to get our revolutionary product through clinical studies and market approval.”
Through the development of the NeokidneyTM home hemodialysis equipment, Nextkidney aims to enhance the quality of life for dialysis patients throughout the world. The firm leverages cutting-edge technology to provide a secure, practical, and simple-to-use solution, placing the patient and their quality of life at the center of its approach. A registered trademark of NextKidney S.A. is The NeokidneyTM.
We try our best to fact-check and bring the best, well-researched, and non-plagiarized content to you. Please let us know
-if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Next Article
 and 7.8 million euros from official and informal investors in France and the Netherlands. The money will be utilized for the company's revolutionary portable device's market approval and clinical studies.){kind=link}